BIODEVICE SYSTEMS SRO

Their core work

Biodevice Systems is a Czech SME specializing in microfluidic diagnostic devices and biosensor platforms for biomedical applications. They develop lab-on-chip systems for real-time biological monitoring, including magnetic diagnostic assays for neurodegenerative diseases and integrated platforms for biomaterial risk assessment. Their core competence lies at the intersection of microfluidics, magnetic nanoparticle-based detection, and biological surface science — translating complex biological measurements into compact, automated device formats.

What they specialise in

How they've shifted over time

Biodevice Systems started with magnetic diagnostic assay development for neurodegenerative diseases (MADIA, 2017), then expanded into integrated biosensor platforms for biomaterial safety testing with real-time monitoring capabilities (PANBioRA, 2018). Their most recent project (BOW, 2020) moves into extracellular vesicle manipulation and nanotoxicity assessment, suggesting a shift from straightforward diagnostics toward more complex biological interaction monitoring at the nanoscale.

They are moving from single-disease diagnostic devices toward broader nano-bio interaction platforms, positioning themselves for the growing regulatory demand around nanosafety and biomaterial testing.

How they like to work

Biodevice Systems operates exclusively as a participant, never coordinating projects, which is typical for a technology SME contributing specialized device capabilities to larger research consortia. With 38 unique partners across 12 countries in just 3 projects, they work in large, diverse consortia (averaging ~13 partners per project). This suggests they are a sought-after specialist that integrates well into multi-partner environments without needing to drive the project agenda.

Despite only three projects, they have built a broad network of 38 partners across 12 countries, indicating participation in large pan-European consortia with wide geographic coverage.

What sets them apart

Biodevice Systems occupies a niche at the intersection of microfluidics and magnetic nanoparticle diagnostics — a combination not common among Czech SMEs. Their progression from disease diagnostics to biomaterial safety to nanotoxicity shows they can adapt their core microfluidic platform to diverse biological assessment needs. For consortium builders, they offer a ready-made capability to miniaturize and automate complex biological assays into device format.

Highlights from their portfolio

• PANBioRA
  Largest funding (EUR 298,125) and broadest scope — integrating immune response, cytotoxicity, genotoxicity, and microbiota analysis into a single personalized biomaterial risk assessment platform.
• BOW
  Most recent and longest-running project (2020-2024), combining extracellular vesicles, magnetic nanoparticles, and nanotoxicity — signals the company's future direction.
• MADIA
  Their first H2020 project, focused on magnetic diagnostic assays for neurodegenerative diseases, establishing their core competence in magnetic biosensing.